CHRM1 and Dyskinesia: Blunting M1R or CDGI signaling in iSPNs not only attenuated the oscillations in dendritic excitability and synaptic strength but also had clear behavioral effects—increasing the symptomatic benefit of levodopa and attenuating on-state dyskinesia.